Deliver Your News to the World

Identifying Fact vs. Fiction on Hermispherx’s (AMEX:HEB) Ampligen


StocksHaven Investments news portal takes a closer look at Hemispherx Biopharma (AMEX:HEB), which hopes its drug, Ampligen will be approved to treat Chronic Fatigue Syndrome (CFS).

Much to the delight of Hemispherx BioPharma individual and institutional investors, a reader and follower of StocksHaven Investments has identified several key points which have been raised recently, decyphering the fact from fiction.

The following article has been submitted by an investor named, Nick DeCesare


After reviewing my own research, it is time to post some serious points, some of which have
already been raised by other great posters, and some have not.

First of all, Mr. Feuerstein has questioned the safety record of Ampligen. The FACT is, when it began as a compassionate emergency treatment (granted by the FDA several years back), that very agency required HEB to submit monthly safety reports. As of approximately one year ago, the FDA contacted HEB via telephone call, to let them know these reports were no longer needed.

The full special article appears today at:

Disclosure: Long-Term Position


About StocksHaven Investments

StocksHaven Investments can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, discussion forum, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit


Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 hemispherx ampligen treat
 cfs treatment ampligen
 stock symbol heb

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.